Cargando…

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature

BACKGROUND: To validate the expression of a urine-based bladder cancer associated diagnostic signature comprised of 10 targets; ANG, CA9, MMP9, MMP10, SERPINA1, APOE, SDC1, VEGFA, SERPINE1 and IL8 in bladder tumor tissues. METHODS: Immunohistochemical analyses were performed on tumor specimens from...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ge, Gomes-Giacoia, Evan, Dai, Yunfeng, Lawton, Adrienne, Miyake, Makito, Furuya, Hideki, Goodison, Steve, Rosser, Charles J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245773/
https://www.ncbi.nlm.nih.gov/pubmed/25387487
http://dx.doi.org/10.1186/s13000-014-0200-1
_version_ 1782346420738588672
author Zhang, Ge
Gomes-Giacoia, Evan
Dai, Yunfeng
Lawton, Adrienne
Miyake, Makito
Furuya, Hideki
Goodison, Steve
Rosser, Charles J
author_facet Zhang, Ge
Gomes-Giacoia, Evan
Dai, Yunfeng
Lawton, Adrienne
Miyake, Makito
Furuya, Hideki
Goodison, Steve
Rosser, Charles J
author_sort Zhang, Ge
collection PubMed
description BACKGROUND: To validate the expression of a urine-based bladder cancer associated diagnostic signature comprised of 10 targets; ANG, CA9, MMP9, MMP10, SERPINA1, APOE, SDC1, VEGFA, SERPINE1 and IL8 in bladder tumor tissues. METHODS: Immunohistochemical analyses were performed on tumor specimens from 213 bladder cancer patients (transitional cell carcinoma only) and 74 controls. Staining patterns were digitally captured and quantitated (Aperio, Vista, CA), and expression was correlated with tumor stage, tumor grade and outcome measures. RESULTS: We revealed a positive association of 9 of the 10 proteins (excluding VEGF) in bladder cancer. Relative to control cases, a reduction in SDC1 and overexpression of MMP9, MMP10, SERPINE1, IL8, APOE, SERPINA1, ANG were associated with high stage bladder cancer. Reduced VEGF and increased SERPINA1 were associated with high-grade bladder cancer. Disease-specific survival was significantly reduced in tumors with high expression of SERPINE1 and/or IL8. CONCLUSIONS: These findings confirm that the proteins in a urine-based diagnostic signature are aberrantly expressed in bladder tumor tissues, and support the potential additional utility of selected biomarkers for the clinicopathological evaluation of excised tissue or biopsy material. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_200
format Online
Article
Text
id pubmed-4245773
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42457732014-11-28 Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature Zhang, Ge Gomes-Giacoia, Evan Dai, Yunfeng Lawton, Adrienne Miyake, Makito Furuya, Hideki Goodison, Steve Rosser, Charles J Diagn Pathol Research BACKGROUND: To validate the expression of a urine-based bladder cancer associated diagnostic signature comprised of 10 targets; ANG, CA9, MMP9, MMP10, SERPINA1, APOE, SDC1, VEGFA, SERPINE1 and IL8 in bladder tumor tissues. METHODS: Immunohistochemical analyses were performed on tumor specimens from 213 bladder cancer patients (transitional cell carcinoma only) and 74 controls. Staining patterns were digitally captured and quantitated (Aperio, Vista, CA), and expression was correlated with tumor stage, tumor grade and outcome measures. RESULTS: We revealed a positive association of 9 of the 10 proteins (excluding VEGF) in bladder cancer. Relative to control cases, a reduction in SDC1 and overexpression of MMP9, MMP10, SERPINE1, IL8, APOE, SERPINA1, ANG were associated with high stage bladder cancer. Reduced VEGF and increased SERPINA1 were associated with high-grade bladder cancer. Disease-specific survival was significantly reduced in tumors with high expression of SERPINE1 and/or IL8. CONCLUSIONS: These findings confirm that the proteins in a urine-based diagnostic signature are aberrantly expressed in bladder tumor tissues, and support the potential additional utility of selected biomarkers for the clinicopathological evaluation of excised tissue or biopsy material. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_200 BioMed Central 2014-11-12 /pmc/articles/PMC4245773/ /pubmed/25387487 http://dx.doi.org/10.1186/s13000-014-0200-1 Text en © Zhang et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhang, Ge
Gomes-Giacoia, Evan
Dai, Yunfeng
Lawton, Adrienne
Miyake, Makito
Furuya, Hideki
Goodison, Steve
Rosser, Charles J
Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
title Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
title_full Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
title_fullStr Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
title_full_unstemmed Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
title_short Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
title_sort validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245773/
https://www.ncbi.nlm.nih.gov/pubmed/25387487
http://dx.doi.org/10.1186/s13000-014-0200-1
work_keys_str_mv AT zhangge validationandclinicopathologicassociationsofaurinebasedbladdercancerbiomarkersignature
AT gomesgiacoiaevan validationandclinicopathologicassociationsofaurinebasedbladdercancerbiomarkersignature
AT daiyunfeng validationandclinicopathologicassociationsofaurinebasedbladdercancerbiomarkersignature
AT lawtonadrienne validationandclinicopathologicassociationsofaurinebasedbladdercancerbiomarkersignature
AT miyakemakito validationandclinicopathologicassociationsofaurinebasedbladdercancerbiomarkersignature
AT furuyahideki validationandclinicopathologicassociationsofaurinebasedbladdercancerbiomarkersignature
AT goodisonsteve validationandclinicopathologicassociationsofaurinebasedbladdercancerbiomarkersignature
AT rossercharlesj validationandclinicopathologicassociationsofaurinebasedbladdercancerbiomarkersignature